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Background: Median overall survival (OS) is w1 year
with pemetrexed/cisplatin, the standard front-line
treatment for patients with unresectable malignant
pleural mesothelioma (MPM); additional improvements
in therapy are needed. Nintedanib is an oral, twice-daily
(bid), triple angiokinase inhibitor of vascular endothelial
growth factor (VEGF) receptors 1e3, platelet-derived
growth factor receptors a/b, and fibroblast growth fac-
tor receptors 1e3, as well as Src and Abl kinases, which
are involved in regulating tumor angiogenesis, growth,
and metastasis of MPM. Inhibition of the VEGF pathway
has been validated as a treatment approach for MPM
with bevacizumab (Zalcman G, et al. Lancet
2016;387:1405e14). Nintedanib (Ofev®) monotherapy
is approved in the USA and EU for idiopathic pulmonary
fibrosis. Nintedanib (VARGATEF®) in combination with
docetaxel is approved in the European Union and other
countries for locally advanced, metastatic or locally
recurrent non-small cell lung cancer of adenocarcinoma
histology after first-line chemotherapy and has shown
clinical benefit in trials in several tumor types. LUME-
Meso is an international, double-blind, randomized,Journal of Thoracic Oncology Vol. 11 No. 10S: S216-S248multicenter, placebo-controlled Phase II/III study, eval-
uating the efficacy and safety of nintedanib combined
with pemetrexed/cisplatin for the treatment of unre-
sectable MPM. Following a data review by the internal
Data Monitoring Committee (DMC) after all planned
Phase II patients had been enrolled, the Phase II
exploratory study was extended to a confirmatory Phase
II/III trial. The trial is ongoing.
Method: Chemo-naïve patients from 27 countries (18
years of age, Eastern Cooperative Oncology Group Perfor-
manceStatus0e1, andhistologically confirmedepithelioid/
biphasicMPM;87pts inPhase II/450pts inPhase III)will be
randomized (1:1) to receive up to 6 cycles of pemetrexed
(500 mg/m2)/cisplatin (75 mg/m2) on Day 1 plus ninte-
danib (200 mg bid) or placebo on Days 2e21. Patients
without disease progression (PD) will continue to receive
maintenance treatment with nintedanib monotherapy/
placebo until PD. The primary endpoint is progression-free
survival (PFS); OS is the key secondary endpoint. The study
will use an adaptive design strategy, with sample size
reassessment by an external DMCbased on interim analysis
to ensure sufficientpower forPFS/OS.Additional secondary
endpoints include objective tumor response and disease
control according to modified Response Evaluation Criteria
in Solid Tumors. Other assessments include frequency/
severity of adverse events, laboratoryparameters, change in
forcedvital capacity (Phase II only), health-relatedquality of
life and exploratory predictive biomarker analyses in tu-
mor/blood specimens.
Results: Not applicable.
Conclusion: The study is currently enrolling patients
into Phase III and will help to determine the efficacy and
safety of nintedanib in patients with unresectable MPM.
Clinical trial identifier: NCT01907100.
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